L-Arginine

• Blood pressure reduction in hypertensive adults (modest, best-supported)
• Erectile dysfunction (modest, mostly combination trials with pycnogenol)
• Wound healing adjunct in clinical nutrition (Arginaid)
• Growth hormone stimulation testing and acute GH response (high doses)
• Cardiovascular function in specific clinical settings (mixed)

L-arginine is a conditionally essential amino acid and the direct biochemical substrate for nitric oxide synthase (NOS), the enzyme family that produces nitric oxide (NO) as the principal vascular signaling molecule. The three NOS isoforms (endothelial eNOS, neuronal nNOS, inducible iNOS) all use L-arginine as substrate, converting it to nitric oxide and L-citrulline through a complex catalytic cycle requiring multiple cofactors (BH4, NADPH, FAD, FMN, heme). Endothelial NOS produces NO in vascular smooth muscle, driving vasodilation, reducing platelet aggregation, and modulating vascular inflammation, the cardiovascular pharmacology that has made arginine one of the most-marketed supplements in history. Beyond NO synthesis, L-arginine participates in the urea cycle (ammonia detoxification), creatine biosynthesis, polyamine synthesis, and protein synthesis as a standard proteinogenic amino acid. The "conditionally essential" classification reflects that endogenous synthesis is generally adequate in healthy adults but becomes insufficient in trauma, sepsis, burns, severe stress, premature infants, and certain genetic conditions. The central pharmacokinetic problem of oral L-arginine, and the reason it has been substantially supplanted by L-citrulline in modern supplement protocols, is intestinal arginase first-pass metabolism. The small intestine and liver express substantial arginase activity, destroying approximately 40-50% of oral L-arginine dose before reaching systemic circulation. This produces modest and short-lived plasma arginine elevation from oral supplementation, limiting the bioavailability achievable through standard dosing. The Schwedhelm 2008 pharmacokinetic comparison demonstrated definitively that equimolar oral L-citrulline produces superior plasma L-arginine elevation versus oral L-arginine, establishing the modern rationale for citrulline supplementation over direct arginine. L-arginine retains specific clinical applications where this pharmacokinetic limitation matters less: wound healing (where local tissue arginine availability matters), pediatric and clinical nutrition (where parenteral or specific delivery routes are used), growth hormone secretagogue testing (high single doses where pharmacokinetic limitations are partially offset by dose), and certain inborn errors of metabolism. For routine cardiovascular and ED consumer supplementation, the L-citrulline route is mechanistically and pharmacokinetically superior.

L-arginine dosing varies substantially by indication and context. For clinical wound healing, Arginaid and similar formulations specify protocol-driven doses under clinical supervision. For growth hormone testing, high single doses (30g IV or 12g oral) are used in endocrinology evaluation. For ED supplementation, 3-6g/day chronically over 4-8 weeks is the historical protocol, though L-citrulline at 1.5-3g/day has substantially supplanted this use case based on superior pharmacokinetics. For cardiovascular and hypertension support, 3-9g/day in divided doses (typically 3 times daily) was historical practice; again L-citrulline at lower doses provides equivalent or superior plasma arginine elevation. Take with or without food; L-arginine is slightly alkaline and some users find taking with food reduces minor GI sensitivity. Effects on cardiovascular and ED endpoints develop over 4-8 weeks of chronic use; acute effects (transient plasma arginine elevation, transient vasodilation) occur within 60-90 minutes of dose. The VINTAGE-MI 2006 mortality signal at 9g/day in post-MI patients warrants caution about high-dose chronic use in established cardiovascular disease; healthy users without cardiovascular disease tolerate standard doses well. The intestinal arginase first-pass metabolism means that doubling oral dose does not double plasma arginine elevation, diminishing returns set in above moderate doses, which is another reason citrulline has become the preferred alternative.

Erectile dysfunction (historical)

3-6g/day chronic (consider L-citrulline alternative)

Cardiovascular (historical)

3-9g/day divided (consider L-citrulline alternative)

Growth hormone testing (clinical)

12g oral or 30g IV per protocol

Clinical wound healing

Per Arginaid protocol

Post-MI safety threshold

AVOID >3g/day without cardiology coordination

Time to acute effect

60-90 minutes for transient plasma elevation

Time to clinical effect (chronic)

4-8 weeks for ED, cardiovascular endpoints

Pharmacokinetic ceiling

Diminishing returns >6g due to first-pass metabolism

• Pharmaceutical-Grade L-Arginine (Pure)

  Rating: gold

  Crystalline white powder, water-soluble (mildly alkaline), used in clinical contexts and pharmaceutical compounding. Available from major supplement manufacturers (NOW Foods, Bulk Supplements, Thorne) at reasonable cost per gram. Ideal for cardiovascular and clinical applications where pure compound is preferred. For most modern consumer NO pathway applications, L-citrulline is the more bioavailable choice.

• L-Arginine HCl (Hydrochloride Salt)

  Rating: good

  Slightly acidic form with improved chemical stability and powder handling versus free-base L-arginine. Functionally equivalent in pharmacology; molecular L-arginine content is slightly lower per gram of compound (accounting for the HCl mass). Common consumer supplement form.

• AAKG (Arginine Alpha-Ketoglutarate)

  Rating: caution

  L-arginine combined with alpha-ketoglutarate (a Krebs cycle intermediate). Heavily marketed in bodybuilding contexts in the 2000s-2010s. The theoretical advantage of alpha-ketoglutarate as Krebs cycle intermediate is mechanistically reasonable but clinical evidence for AAKG superiority over pure L-arginine is limited. The brand-driven category has substantially declined as citrulline malate has become the dominant pre-workout amino acid.

• Arginaid (Clinical Wound Healing Formulation)

  Rating: gold

  Pharmaceutical clinical nutrition product containing L-arginine, vitamin C, vitamin E, and other wound-healing nutrients in specific ratios. Used in hospital and outpatient wound care contexts under clinical supervision. Among the most-evidenced specific L-arginine clinical applications. Not a consumer supplement.

• L-Arginine + L-Citrulline Combinations

  Rating: good

  Combined supplementation may provide immediate (direct arginine) and sustained (citrulline-to-arginine conversion) NO pathway support. Suzuki 2017 work suggests the combination may produce more sustained plasma arginine elevation than either compound alone. Reasonable for users wanting comprehensive NO pathway support.

• IV L-Arginine (Clinical / Hospital)

  Rating: gold

  Hospital IV formulations used for growth hormone stimulation testing, parenteral nutrition in specific contexts, and certain inborn errors of metabolism. The pharmaceutical-grade clinical L-arginine source. Not a consumer supplement form.

• L-Arginine Capsules

  Rating: good

  Capsule delivery typically 500-1500mg per capsule. Acceptable for users preferring capsule format; powder is more cost-effective for higher doses. For most modern consumer NO pathway applications, capsule L-citrulline is the preferred alternative.

• Branded "Cardiovascular Health" Products

  Rating: caution

  Multi-ingredient cardiovascular supplements often include L-arginine alongside CoQ10, omega-3, vitamin K2, and other cardiovascular nutrients. Quality and dose disclosure varies enormously; "ProArgi-9 Plus" and similar branded products have been marketed for cardiovascular health with claims that exceed the underlying evidence base. Verify individual ingredient doses rather than relying on branded category positioning.

• Clinical wound healing (surgical, immunocompromised)

  Strength of evidence for this group: modest

  The strongest L-arginine clinical case. Arginaid and similar clinical nutrition formulations have established evidence in surgical wound healing, immunocompromised wound contexts, and specific catabolic states. Specialist coordination through clinical nutrition or wound care.

• Growth hormone stimulation testing

  Strength of evidence for this group: strong

  Pharmaceutical L-arginine is established for growth hormone stimulation testing in endocrinology, high-dose IV or oral arginine produces measurable GH elevation that informs diagnostic evaluation of GH deficiency. Clinical use under endocrinology supervision.

• Erectile dysfunction (mild to moderate)

  Strength of evidence for this group: modest

  Chen 1999 and subsequent modest trials support some ED benefit at high doses (5g/day) chronically. Effect sizes substantially smaller than PDE5 inhibitors. For most modern ED supplement applications, L-citrulline at lower doses has supplanted L-arginine due to superior pharmacokinetics.

• Hypertension (mild)

  Strength of evidence for this group: modest

  Mechanistically reasonable; clinical evidence is preliminary and effect sizes are modest. Largely supplanted by L-citrulline at similar or lower doses for the same NO pathway support. Coordinate with cardiology for established hypertension management.

• Heart failure (adjunct)

  Strength of evidence for this group: cautious

  Mixed evidence base. Some short-term trials show vascular endothelial function improvement; longer-term trials have been less consistent. Not standard heart failure adjunctive therapy. Coordinate with cardiology.

• Post-myocardial infarction patients

  Strength of evidence for this group: cautious

  The VINTAGE-MI 2006 trial showed increased mortality at 9g/day in post-MI patients, a meaningful safety signal that warrants caution about high-dose L-arginine in established cardiovascular disease. Specialist guidance required; generally avoid high-dose chronic L-arginine post-MI without cardiology coordination.

• Herpes simplex (HSV-1, HSV-2) frequent reactivators

  Strength of evidence for this group: cautious

  The lysine-arginine ratio theory of HSV reactivation is well-established. Users with frequent HSV outbreaks may experience increased outbreak frequency with high-dose arginine supplementation. Reasonable to avoid or minimize; L-lysine supplementation may be preferred for this cohort.

• Preeclampsia prevention (high-risk pregnancy)

  Strength of evidence for this group: cautious

  Preliminary evidence from Dorniak-Wall 2014 and subsequent trials suggests possible benefit in preeclampsia risk reduction. Not standard obstetric practice; coordinate with maternal-fetal medicine for high-risk pregnancy contexts. Most healthy pregnancies do not warrant L-arginine supplementation.

• L-Citrulline

  Interaction: synergy

  Mechanistically complementary, citrulline provides sustained plasma arginine elevation through kidney conversion; direct arginine provides immediate availability. Combined dosing may produce more sustained NO pathway support than either alone. Reasonable comprehensive cardiovascular and ED protocol; for most consumer applications, L-citrulline alone is sufficient and more cost-effective.

• L-Lysine

  Interaction: caution

  The lysine-arginine ratio theory for HSV reactivation suggests that L-lysine supplementation can counter arginine's effects on HSV. Concurrent supplementation in users with frequent HSV outbreaks is mechanistically counterproductive; L-lysine alone or arginine restriction is preferred for this cohort.

• PDE5 Inhibitors (Sildenafil, Tadalafil)

  Interaction: caution

  Both mechanisms support nitric oxide pathway and vasodilation. Theoretical additive hypotension warrants caution, particularly in users on antihypertensives. Coordinate with prescribing physician for combined ED management. The clinical effects of PDE5 inhibitors are substantially larger than oral arginine; combination is uncommon in practice.

• Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers)

  Interaction: caution

  Additive blood pressure-lowering effects. Monitor BP when initiating L-arginine in users on antihypertensive therapy; medication dose adjustment may be needed. Generally well-tolerated at modest arginine doses.

• Anticoagulants (Warfarin, DOACs)

  Interaction: caution

  L-arginine has mild antiplatelet activity through NO pathway support. Theoretical additive bleeding risk with anticoagulant therapy; clinical significance modest. Coordinate with prescribing physician.

• Nitrate Medications

  Interaction: caution

  Additive vasodilation and hypotension. Coordinate with cardiology for users on nitrate therapy; concurrent use is generally avoided.

• Pre-Surgery Period

  Interaction: caution

  Vasodilation and mild antiplatelet effects warrant 1-2 week discontinuation before elective surgery as conservative practice. Coordinate with anesthesiology for emergency procedures.

• Post-Myocardial Infarction

  Interaction: avoid

  The VINTAGE-MI 2006 mortality signal at 9g/day in post-MI patients warrants avoidance of high-dose chronic L-arginine in established post-MI cardiovascular disease. Specialist guidance required.

• Active Herpes Simplex Reactivation

  Interaction: avoid

  Lysine-arginine ratio mechanism may worsen HSV outbreaks. Avoid or minimize during active outbreaks; L-lysine alternative for frequent HSV users.

Look for: pure L-arginine or L-arginine HCl specified clearly on label; third-party verification (NSF, USP) for chronic use; reasonable price per gram (L-arginine is genuinely affordable at commodity pricing); transparent dose disclosure rather than proprietary blends. Avoid: AAKG and other branded forms at premium pricing without specific evidence of superiority; proprietary "cardiovascular" or "NO booster" blends that obscure individual ingredient doses; products from manufacturers without third-party testing disclosure; products marketed with cardiovascular health claims that exceed the underlying evidence base. For most consumer NO pathway applications, L-citrulline is the more cost-effective and pharmacokinetically superior alternative.

L-arginine's scientific history begins in 1886 with Ernst Schulze and Ernst Steiger at the Swiss Federal Institute of Technology Zürich. They isolated the amino acid from lupine seedlings, establishing the foundational botanical chemistry and naming the compound after argentum (Latin for silver) due to its characteristic silver-nitrate crystallization. The structural characterization developed through the early 20th century, establishing L-arginine as one of the twenty standard proteinogenic amino acids and characterizing its role in the urea cycle (alongside the Krebs and Henseleit work that established citrulline's metabolic role). The cardiovascular pharmacology era began in the 1980s with Robert Furchgott's identification of endothelium-derived relaxing factor (EDRF), the previously-uncharacterized molecule responsible for endothelium-mediated vasodilation. Subsequent work by Louis Ignarro, Salvador Moncada, and Ferid Murad identified EDRF as nitric oxide and characterized L-arginine as the NOS substrate. The 1998 Nobel Prize in Physiology or Medicine (Furchgott, Ignarro, Murad) recognized this foundational cardiovascular pharmacology, establishing L-arginine's mechanistic position as the most important amino acid in vascular biology. The consumer supplement era expanded substantially through the 1990s and 2000s. L-arginine was heavily marketed for cardiovascular health, erectile dysfunction, athletic performance, and growth hormone elevation. The Chen 1999 ED trial and subsequent work established the modest ED case; the Welbourne 1995 work established the GH secretagogue use case; the Lubec 1996 wound healing meta-analysis established the clinical wound healing case. The supplement category grew to substantial commercial scale. The inflection point was the 2006 publication of VINTAGE-MI in JAMA. The trial randomized 153 post-myocardial infarction patients to 3g L-arginine three times daily (9g/day total) versus placebo. The trial was terminated early due to increased mortality in the L-arginine arm, a major safety signal that reshaped post-MI guidance and warranted general caution about high-dose chronic L-arginine in established cardiovascular disease. The finding had substantial implications for the consumer supplement market. The 2008 Schwedhelm pharmacokinetic comparison in the British Journal of Clinical Pharmacology then established that oral L-citrulline produces superior plasma L-arginine elevation versus equimolar oral L-arginine, definitively documenting the intestinal arginase first-pass metabolism problem. The combination of the VINTAGE-MI safety signal (limiting high-dose use) and the citrulline pharmacokinetic superiority (offering a better alternative for the same use cases) catalyzed substantial decline of the L-arginine consumer supplement category over the 2010s and 2020s. L-arginine retains specific clinical applications (Arginaid wound healing, GH testing, inborn errors of metabolism) but has been substantially supplanted in consumer supplementation by L-citrulline. The story is an unusually clear case of evidence-driven supplement market evolution, both a major safety signal (VINTAGE-MI) and a superior alternative (L-citrulline) emerged within a few years, and the consumer category responded over the following decade. It is also a clear case of the M-08 Replication-Discordance methodology dimension at a category level: foundational positive trials and aggressive consumer marketing, complicated by subsequent safety signals and pharmacokinetic findings that supported a substantially supplanted alternative.

1. 1886Schulze and Steiger isolate L-arginine from lupine seedlings
2. 1932Krebs and Henseleit elucidate urea cycle; arginine role established
3. 1980Furchgott identifies endothelium-derived relaxing factor (EDRF)
4. 1987EDRF identified as nitric oxide; L-arginine as NOS substrate
5. 1995Welbourne establishes growth hormone secretagogue role
6. 1996Bode-Böger oral pharmacokinetics; Lubec wound healing meta-analysis
7. 1998Nobel Prize for nitric oxide cardiovascular pharmacology (Furchgott, Ignarro, Murad)
8. 1999Chen erectile dysfunction modest evidence trial
9. 2006VINTAGE-MI mortality signal in post-MI patients
10. 2008Schwedhelm establishes L-citrulline pharmacokinetic superiority
11. 2010sConsumer market substantial shift from L-arginine to L-citrulline
12. 2014Dorniak-Wall preeclampsia prevention review (modest evidence)

• Whether L-arginine retains specific clinical applications where direct arginine availability matters more than the pharmacokinetic-superior L-citrulline route (wound healing, GH testing, specific pediatric clinical contexts).
• Whether the VINTAGE-MI mortality signal generalizes to all chronic cardiovascular disease populations or is specific to the immediate post-MI period.
• Whether modest doses (1-3g/day) in healthy users without cardiovascular disease carry any of the high-dose post-MI safety concerns.
• Whether preeclampsia prevention evidence will resolve into established obstetric practice or remain preliminary.
• Whether the L-arginine + L-citrulline combination produces clinically meaningful advantage over L-citrulline alone for the consumer cardiovascular and ED use cases.
• How best to integrate the herpes simplex reactivation concern into consumer guidance, current framing is often missing from L-arginine marketing.
• Whether AAKG (arginine alpha-ketoglutarate) and other branded forms produce clinically distinguishable outcomes versus pure L-arginine, generally not supported by available evidence.

Universally available globally as a dietary supplement. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pharmaceutical-grade L-arginine is also used in clinical contexts (Arginaid clinical wound healing nutrition, IV formulations for growth hormone testing and parenteral nutrition) at higher cost. Major retail brands include NOW Foods, Thorne, Bulk Supplements, Solgar, and historical bodybuilding brands. Production is dominated by microbial fermentation and chemical synthesis at commodity pricing; supply is broadly accessible. The L-arginine supplement category has substantially declined in commercial prominence over the past decade as L-citrulline has supplanted the consumer NO pathway use case, a clear example of evidence-driven supplement market evolution.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Structure

Standard proteinogenic amino acid with guanidinium side chain

Endogenous role

NO synthase substrate; urea cycle intermediate; creatine biosynthesis

Standard dietary intake

4-6g/day from adequate protein intake

Pharmacokinetic limitation

40-50% first-pass metabolism by intestinal arginase

Standard supplement dose

3-9g/day in divided doses

GH testing dose

12g oral or 30g IV

What follows is unfinished work on our side, not a finding about L-Arginine. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.